FOXD1 and neoplasm: Since there are a large number of patients with head and neck cancer who are resistant to cetuximab, we wondered whether it was related to the abnormally high expression of FOXD1 in the tumor, so we established a cell line that overexpressed FOXD1 and passed cetuximab treatment of drugs.